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Introduction: Patients with interstitial lung diseases (ILD) can be suspected to be at risk of
experiencing a rapid flare-up due to COVID-19. However, no specific data are currently
available for these patients.
Methods: We retrospectively analyzed a cohort of 401 patients with ILD and determined the
proportion of patients hospitalized for proven severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19.
Results: We found that 1% of patients (n ¼ 4) were hospitalized (1 in ICU) for COVID-19. In
total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced
specific symptoms of SARS-CoV-2 infection.
Conclusion: Our study did not demonstrate any increased occurrence of severe COVID-19 in
ILD patients compared to the global population. Based on our findings, we could not make
any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on
the overall outcome of immunocompromised patients affected by COVID-19.
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Belgium, a massive lockdown has been enforced to limit the
spread of this pandemic. Presently, more than 51.000 cases
have been reported in our country (out of 11.5 million living
persons, with 18,8% of the population being over 65 years of
age). COVID-19 can induce severe lung injury leading to ARDS
(acute respiratory distress syndrome), mainly in older patients,
and the global mortality rate in our country is averaging 16%
among the infected patients [1]. Patients suffering from inter-
stitial lung diseases (ILDs) can be suspected to be at a high risk
of experiencing a rapid flare-up due to COVID-19. This hy-
pothesis is based on the underlying diseases and the median
age of such a population (above 60 years). However, it is also
based on the risk associated with specific therapies, such as
immunosuppressive therapies in connective tissue diseases
associated with pulmonary fibrosis (CTD-PF) and anti-fibrotic
therapies in idiopathic pulmonary fibrosis (IPF).
To address this hypothesis, we aimed to determine the spe-
cific incidence of symptomatic COVID-19 in patients with ILD.
We analyzed our database of ILD patients (n ¼ 627) who were
followed-up in Liege University Hospital. We excluded patients
who did not benefit from regular clinical monitoring as well as
patients who died before January 2020. We then investigated
whether thosepatientswhowere closely followed-up inour ILD
center (n ¼ 401) were tested positive for COVID-19 or hospital-
ized in this context. Moreover, in our clinical phone-based
follow-up, we analyzed the proportion of patients who did not
experienceany specific symptomsofCOVID-19 (77%answered).
Patients who were not hospitalized were not allowed to be un-
dergo the specific PCR testing, whichwas solely reserved for the
most severe cases during this pandemic. The average age of ILD
patients was 64 ± 16 years with a female predominance. This
cohort was composed of patients with systemic sclerosis-
associated ILD (SSc-ILD), IPF, sarcoidosis, CTD-PF, fibrosingTable 1 e Clinical characteristics of patients with COVID-19 an
All hospitalized with
COVID-19 in CHU Liege
n ¼ 687 Case 1 Ca
n (%) SSc-ILD Sarc
Gender, M (%) 315 (53%) F M
Age, Year 58 ± 20 45 37
Symptoms Cough, N (%) 268 (84%) Yes Y
Dyspnea 162 (51%) e Y
Chest pain 105 (33%) e e
Rhinorrhea 167 (52%) Yes e
Diarrhea 99 (31%) e e
Hyperthermia 216 (68%) Yes Y
Asthenia 201 (63%) e Y
Cephalalgia 202 (64%) e Y
Hospitalization 406 (59%) 8 days 5




The data for symptoms are available for only 318 COVID-19 patients.
ECI: enzyme conversion inhibitor; CS: corticosteroids (Prednisolone); I
Mycophenolate Mofetil, Ledertrexate); ICU: intensive care unit; ILD: inter
lung disease.
All the ILD patients were contacted by phone (at least 2 attempts). In tota
when they experienced at least one of the COVID-19-specific symptomsnon-specific interstitial pneumonia, and other ILDs (15.7%;
11.2%; 11.6%; 18.5%; 10.3%; and 32.7%, respectively). In our
cohort, 37% of the patients were administered specific immu-
nosuppressive therapy (prednisolone >5 mg/day, mycopheno-
late mofetil, azathioprine, or methotrexate). We compared the
four hospitalized PCR-confirmed COVID-19 patients and those
with specific symptoms (nothospitalized) to ourhospital cohort
of patients with a proven severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection (PCR-positive) (n ¼ 687)
without any underlying ILD. Confirmed cases of COVID-19were
identified through rhinopharyngeal swabs.
Different viral agents are associatedwithan increased risk of
a more severe disease course and respiratory complications in
immunocompromised patients [2]. Surprisingly, we found that
only 4 patients (2 men/2 women) were hospitalized for COVID-
19 out of the 401 selected patients, which is in line with the
global incidence of the disease [3,4]. Those 4 patients where
suffering from SSc-ILD, hypersensitivity pneumonitis, sarcoid-
osis, and lipidic pneumopathy, respectively. The fourth patient
was admitted to the ICU and is now discharged. Shewas not on
any specific background therapy. All the four patients received
at least an antibiotic course (amoxicillin þ clavulanic acid),
empirically associatedwith hydroxychloroquine. None of them
benefited fromplasma therapy or anti-viral therapy. As of now,
there has been no significant relapse of their underlying ILD.
After calling the other ILDoutpatients,we found that 33 of them
experienced specific symptoms of SARS-CoV-2 infection and
met theCOVID-19 screening criteria (Table 1) [5]. The symptoms
are presented in Table 1 andweremainly cough (67%), dyspnea
(58%), rhinorrhea (42%),hyperthermia (48%),andasthenia (51%).
Only two of them where tested and recognized as positive for
COVID-19.
This observation corroborates with the global incidence of
COVID-19. Unsurprisingly, since the severe respiratoryd patients of our ILD cohort.
ILD (n ¼ 400)
se 2 Case 3 Case 4 Suggestive
oidosis Chronic HP Lipidic Pneumopathy n ¼ 33
M F 20 (61%)
79 74 60 ± 14
es Yes Yes 22 (67%)
es Yes Yes 19 (58%)
e e e
e Yes 14 (42%)
e e 5 (15%)
es Yes Yes 16 (48%)
es Yes Yes 17 (51%)
es Yes e 9 (27%)
days >7 days >7 days 5 (15%)
e 6 days
CS 5 mg/d ICS high dose CS 14 (42%)
IS 10 (30%)
CS: inhaled corticosteroids; IS: immunosuppressors (Azathioprine,
stitial lung disease; SSc-ILD: systemic sclerosis-associated interstitial
l, 77% of them responded. Patients were suspected to have COVID-19
of acute onset.
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to be driven by the aberrant inflammatory and cytokine re-
sponses perpetuated by the host's immune system [6], patients
benefiting from immunosuppressive therapy could hypotheti-
cally be at a low risk of ARDS. Contrary to this, however,
immunosuppressive therapies may lead the patients to an
immunocompromised state, which could result in severe in-
fectious diseases with lethal respiratory failure such as pneu-
mocystis pneumonia or cytomegalovirus infection that can
increase the risk of non-COVID-19-related severe respiratory
failure. We cannot conclude from such a small cohort that ILD
patients could be at increased risk of SARS-CoV-2 infection.
Nevertheless, the main limitation of this study is the highly
preventive intervention of the Belgian government and the
awareness of ILD patients that they may be at risk of experi-
encing a severe form of pulmonary involvement and their
consequent containment. Through these observations, it seems
essential to maintain active observation of our patients to
identify a resurgence of this infection in this specific group of
fragile patients. Notably, one study focusing on patients with
rheumatoid arthritis [7] implemented these observations. They
identified4out of 320patients positive for SARS-CoV-2 infection
and 4 with suggestive symptoms but without positive PCR re-
sults. Another study on 530 patients identified that 2% of the
patients were suspected to be positive [8].
Our findings do not allow us to draw any conclusion
regarding the incidence rate ofSARS-CoV-2 infection inpatients
with ILDs, or on the overall outcome of immunocompromised
patients affected by COVID-19. By following-up these patients,
wecouldpossiblyhighlightahypotheticalunexpectedbenefitof
certaintherapies.Forexample, immunosuppressivetreatments
pursued by necessity or anti-fibrotic treatments maintained to
reduce the evolution of IPF should be specifically reported
within cohorts of patients suffering from COVID-19.
Although continuous surveillance of patients with ILDs
receiving immunosuppressive drugs is warranted [9,10], these
data can support clinicians in themanagement and counselling
of their patients and in avoiding the unjustifiable preventive
withdrawalof immunosuppressive therapy,whichcould leadto
an increased risk of relapses and morbidity linked to uncon-
trolled chronic ILDs.Author agreement
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